Perspective Therapeutics, Inc. revenue
Perspective Therapeutics, Inc.'s revenue was $1.4m in fiscal 2023. Since fiscal 2011 ($5.2m) it has grown at a compound -10.2% a year.
Revenue history
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Dec 2022 | 2023Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 6 | 7 | 10 | 10 | 0 | 1 |
| Growth on the year before | — | −3.2% | −10.8% | −6.8% | +9.2% | +3.5% | −0.2% | +24.4% | +23.5% | +32.3% | +3.9% | −100.0% | — |
| Gross profit | 1 | 1 | 0 | −0 | 0 | 0 | 1 | 2 | 3 | 5 | 5 | — | 1 |
| Gross margin | 22.1% | 13.9% | 3.3% | −4.7% | 3.6% | 2.7% | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | — | 100.0% |
| Quarter | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 | 2023 Q1Mar 2023 | 2023 Q2Jun 2023 | 2023 Q3Sept 2023 | 2023 Q4Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,910 | 2,505 | 1,717 | 1,835 | 2,063 | 2,088 | 2,185 | −4,902 |
| Growth on the same quarter a year before | — | — | — | — | −29.1% | −16.6% | +27.3% | −367.1% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Perspective Therapeutics, Inc. | $1.4m | -84.0% | -47.5% |
| Cartesian Therapeutics, Inc. | $1.5m | 44.0% | -68.8% |
| Dare Bioscience, Inc. | $1.4m | 4366.5% | — |
| Absci Corp | $1.6m | -62.3% | -43.3% |
| Ovid Therapeutics Inc. | $1.6m | -76.2% | 99.8% |
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies